Skip to main content
NCBI home page
Biochemical Journal logoLink to Biochemical Journal
. 1999 May 1;339(Pt 3):607–614.

Kinetic basis for selective inhibition of cyclo-oxygenases.

J K Gierse 1, C M Koboldt 1, M C Walker 1, K Seibert 1, P C Isakson 1
PMCID: PMC1220196  PMID: 10215599

Abstract

Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit the formation of prostaglandins by cyclo-oxygenases (COX). The discovery of a second COX isoform (COX-2) associated with inflammation led to agents that selectively inhibit COX-2, e.g. celecoxib. We evaluated the kinetics of inhibition of celecoxib and several NSAIDs. Celecoxib displays classic competitive kinetics on COX-1 (Ki=10-16 microM). An initial competitive interaction with COX-2 can also be discerned with celecoxib (Ki=11-15 microM), followed by a time-dependent interaction leading to potent inhibition, characterized as inactivation (Kinact=0.03-0.5 s-1). Half-maximal inhibition (IC50) using end-point assays reflects the competitive component on COX-1 (IC50=4-19 microM) and the inactivation component on COX-2 (IC50=0.003-0.006 microM). NSAIDs exhibit four distinct modes of COX inhibition based on kinetic behaviour: (1) competitive, e.g. ibuprofen; (2) weak binding, time-dependent, e.g. naproxen, oxicams; (3) tight binding, time-dependent, e.g. indomethacin; (4) covalent, e.g. aspirin. In addition, most NSAIDs display different kinetic behaviour for each isoform. Weakly binding inhibitors show variable behaviour in enzyme assays, with apparent inhibitory activity being markedly influenced by experimental conditions; determination of kinetic constants with this class is unreliable and IC50 values are strongly dependent on assay conditions. Although IC50 determinations are useful for structure/activity analyses, the complex and distinct mechanisms of enzyme inhibition of each COX isoform by the NSAIDs renders comparison of inhibitory activity on COX-1 and COX-2 using IC50 ratios of questionable validity.

Full Text

The Full Text of this article is available as a PDF (152.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barnett J., Chow J., Ives D., Chiou M., Mackenzie R., Osen E., Nguyen B., Tsing S., Bach C., Freire J. Purification, characterization and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus system. Biochim Biophys Acta. 1994 Nov 16;1209(1):130–139. doi: 10.1016/0167-4838(94)90148-1. [DOI] [PubMed] [Google Scholar]
  2. Callan O. H., So O. Y., Swinney D. C. The kinetic factors that determine the affinity and selectivity for slow binding inhibition of human prostaglandin H synthase 1 and 2 by indomethacin and flurbiprofen. J Biol Chem. 1996 Feb 16;271(7):3548–3554. doi: 10.1074/jbc.271.7.3548. [DOI] [PubMed] [Google Scholar]
  3. Copeland R. A., Williams J. M., Giannaras J., Nurnberg S., Covington M., Pinto D., Pick S., Trzaskos J. M. Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase. Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):11202–11206. doi: 10.1073/pnas.91.23.11202. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Fu J. Y., Masferrer J. L., Seibert K., Raz A., Needleman P. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem. 1990 Oct 5;265(28):16737–16740. [PubMed] [Google Scholar]
  5. Futaki N., Takahashi S., Yokoyama M., Arai I., Higuchi S., Otomo S. NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins. 1994 Jan;47(1):55–59. doi: 10.1016/0090-6980(94)90074-4. [DOI] [PubMed] [Google Scholar]
  6. Gierse J. K., Hauser S. D., Creely D. P., Koboldt C., Rangwala S. H., Isakson P. C., Seibert K. Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase. Biochem J. 1995 Jan 15;305(Pt 2):479–484. doi: 10.1042/bj3050479. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Gierse J. K., McDonald J. J., Hauser S. D., Rangwala S. H., Koboldt C. M., Seibert K. A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors. J Biol Chem. 1996 Jun 28;271(26):15810–15814. doi: 10.1074/jbc.271.26.15810. [DOI] [PubMed] [Google Scholar]
  8. Guo Q., Wang L. H., Ruan K. H., Kulmacz R. J. Role of Val509 in time-dependent inhibition of human prostaglandin H synthase-2 cyclooxygenase activity by isoform-selective agents. J Biol Chem. 1996 Aug 9;271(32):19134–19139. doi: 10.1074/jbc.271.32.19134. [DOI] [PubMed] [Google Scholar]
  9. Hla T., Neilson K. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7384–7388. doi: 10.1073/pnas.89.16.7384. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. KITZ R., WILSON I. B. Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase. J Biol Chem. 1962 Oct;237:3245–3249. [PubMed] [Google Scholar]
  11. Kujubu D. A., Fletcher B. S., Varnum B. C., Lim R. W., Herschman H. R. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem. 1991 Jul 15;266(20):12866–12872. [PubMed] [Google Scholar]
  12. Kurumbail R. G., Stevens A. M., Gierse J. K., McDonald J. J., Stegeman R. A., Pak J. Y., Gildehaus D., Miyashiro J. M., Penning T. D., Seibert K. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature. 1996 Dec 19;384(6610):644–648. doi: 10.1038/384644a0. [DOI] [PubMed] [Google Scholar]
  13. Lecomte M., Laneuville O., Ji C., DeWitt D. L., Smith W. L. Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin. J Biol Chem. 1994 May 6;269(18):13207–13215. [PubMed] [Google Scholar]
  14. Lora M., Morisset S., Ménard H. A., Leduc R., de Brum-Fernandes A. J. Expression of recombinant human cyclooxygenase isoenzymes in transfected COS-7 cells in vitro and inhibition by tenoxicam, indomethacin and aspirin. Prostaglandins Leukot Essent Fatty Acids. 1997 May;56(5):361–367. doi: 10.1016/s0952-3278(97)90584-6. [DOI] [PubMed] [Google Scholar]
  15. Masferrer J. L., Zweifel B. S., Manning P. T., Hauser S. D., Leahy K. M., Smith W. G., Isakson P. C., Seibert K. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3228–3232. doi: 10.1073/pnas.91.8.3228. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Meade E. A., Smith W. L., DeWitt D. L. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 1993 Mar 25;268(9):6610–6614. [PubMed] [Google Scholar]
  17. Mizuno K., Yamamoto S., Lands W. E. Effects of non-steroidal anti-inflammatory drugs on fatty acid cyclooxygenase and prostaglandin hydroperoxidase activities. Prostaglandins. 1982 May;23(5):743–757. [PubMed] [Google Scholar]
  18. Needleman P., Turk J., Jakschik B. A., Morrison A. R., Lefkowith J. B. Arachidonic acid metabolism. Annu Rev Biochem. 1986;55:69–102. doi: 10.1146/annurev.bi.55.070186.000441. [DOI] [PubMed] [Google Scholar]
  19. O'Banion M. K., Winn V. D., Young D. A. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc Natl Acad Sci U S A. 1992 Jun 1;89(11):4888–4892. doi: 10.1073/pnas.89.11.4888. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. O'Neill G. P., Mancini J. A., Kargman S., Yergey J., Kwan M. Y., Falgueyret J. P., Abramovitz M., Kennedy B. P., Ouellet M., Cromlish W. Overexpression of human prostaglandin G/H synthase-1 and -2 by recombinant vaccinia virus: inhibition by nonsteroidal anti-inflammatory drugs and biosynthesis of 15-hydroxyeicosatetraenoic acid. Mol Pharmacol. 1994 Feb;45(2):245–254. [PubMed] [Google Scholar]
  21. Penning T. D., Talley J. J., Bertenshaw S. R., Carter J. S., Collins P. W., Docter S., Graneto M. J., Lee L. F., Malecha J. W., Miyashiro J. M. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). J Med Chem. 1997 Apr 25;40(9):1347–1365. doi: 10.1021/jm960803q. [DOI] [PubMed] [Google Scholar]
  22. Picot D., Loll P. J., Garavito R. M. The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature. 1994 Jan 20;367(6460):243–249. doi: 10.1038/367243a0. [DOI] [PubMed] [Google Scholar]
  23. Riendeau D., Percival M. D., Boyce S., Brideau C., Charleson S., Cromlish W., Ethier D., Evans J., Falgueyret J. P., Ford-Hutchinson A. W. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br J Pharmacol. 1997 May;121(1):105–117. doi: 10.1038/sj.bjp.0701076. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Rome L. H., Lands W. E. Structural requirements for time-dependent inhibition of prostaglandin biosynthesis by anti-inflammatory drugs. Proc Natl Acad Sci U S A. 1975 Dec;72(12):4863–4865. doi: 10.1073/pnas.72.12.4863. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Rosen G. D., Birkenmeier T. M., Raz A., Holtzman M. J. Identification of a cyclooxygenase-related gene and its potential role in prostaglandin formation. Biochem Biophys Res Commun. 1989 Nov 15;164(3):1358–1365. doi: 10.1016/0006-291x(89)91819-6. [DOI] [PubMed] [Google Scholar]
  26. Seibert K., Masferrer J. L. Role of inducible cyclooxygenase (COX-2) in inflammation. Receptor. 1994 Spring;4(1):17–23. [PubMed] [Google Scholar]
  27. So O. Y., Scarafia L. E., Mak A. Y., Callan O. H., Swinney D. C. The dynamics of prostaglandin H synthases. Studies with prostaglandin h synthase 2 Y355F unmask mechanisms of time-dependent inhibition and allosteric activation. J Biol Chem. 1998 Mar 6;273(10):5801–5807. doi: 10.1074/jbc.273.10.5801. [DOI] [PubMed] [Google Scholar]
  28. Vane J. R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971 Jun 23;231(25):232–235. doi: 10.1038/newbio231232a0. [DOI] [PubMed] [Google Scholar]
  29. Wong E., Bayly C., Waterman H. L., Riendeau D., Mancini J. A. Conversion of prostaglandin G/H synthase-1 into an enzyme sensitive to PGHS-2-selective inhibitors by a double His513 --> Arg and Ile523 --> val mutation. J Biol Chem. 1997 Apr 4;272(14):9280–9286. doi: 10.1074/jbc.272.14.9280. [DOI] [PubMed] [Google Scholar]
  30. Xie W. L., Chipman J. G., Robertson D. L., Erikson R. L., Simmons D. L. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci U S A. 1991 Apr 1;88(7):2692–2696. doi: 10.1073/pnas.88.7.2692. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

RESOURCES